Literature DB >> 33505964

Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming.

Sen Yang1, Qiaofei Liu1, Quan Liao1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy. PDAC is only cured by surgical resection in its early stage, but there remains a relatively high possibility of recurrence. The development of PDAC is closely associated with the tumor microenvironment. Tumor-associated macrophages (TAMs) are one of the most abundant immune cell populations in the pancreatic tumor stroma. TAMs are inclined to M2 deviation in the tumor microenvironment, which promotes and supports tumor behaviors, including tumorigenesis, immune escape, metastasis, and chemotherapeutic resistance. Herein, we comprehensively reviewed the latest researches on the origin, polarization, functions, and reprogramming of TAMs in PDAC.
Copyright © 2021 Yang, Liu and Liao.

Entities:  

Keywords:  origin; pancreatic ductal adenocarcinoma; polarization; reprogramming; tumor-associated macrophages

Year:  2021        PMID: 33505964      PMCID: PMC7829544          DOI: 10.3389/fcell.2020.607209

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  231 in total

1.  TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis.

Authors:  Tokuhiro Matsubara; Tatsuya Kanto; Shoko Kuroda; Sachiyo Yoshio; Koyo Higashitani; Naruyasu Kakita; Masanori Miyazaki; Mitsuru Sakakibara; Naoki Hiramatsu; Akinori Kasahara; Yoshito Tomimaru; Akira Tomokuni; Hiroaki Nagano; Norio Hayashi; Tetsuo Takehara
Journal:  Hepatology       Date:  2013-02-11       Impact factor: 17.425

Review 2.  Tissue-Resident Macrophage Ontogeny and Homeostasis.

Authors:  Florent Ginhoux; Martin Guilliams
Journal:  Immunity       Date:  2016-03-15       Impact factor: 31.745

Review 3.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Trends Pharmacol Sci       Date:  2012-03-06       Impact factor: 14.819

4.  The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.

Authors:  Allison S Harney; George S Karagiannis; Jeanine Pignatelli; Bryan D Smith; Ece Kadioglu; Scott C Wise; Molly M Hood; Michael D Kaufman; Cynthia B Leary; Wei-Ping Lu; Gada Al-Ani; Xiaoming Chen; David Entenberg; Maja H Oktay; Yarong Wang; Lawrence Chun; Michele De Palma; Joan G Jones; Daniel L Flynn; John S Condeelis
Journal:  Mol Cancer Ther       Date:  2017-08-24       Impact factor: 6.261

5.  GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GABA-independent manner.

Authors:  Shu-Heng Jiang; Li-Li Zhu; Man Zhang; Rong-Kun Li; Qin Yang; Jiang-Yu Yan; Ce Zhang; Jian-Yu Yang; Fang-Yuan Dong; Miao Dai; Li-Peng Hu; Jun Li; Qing Li; Ya-Hui Wang; Xiao-Mei Yang; Yan-Li Zhang; Hui-Zhen Nie; Lei Zhu; Xue-Li Zhang; Guang-Ang Tian; Xiao-Xin Zhang; Xiao-Yan Cao; Ling-Ye Tao; Shan Huang; Yong-Sheng Jiang; Rong Hua; Kathy Qian Luo; Jian-Ren Gu; Yong-Wei Sun; Shangwei Hou; Zhi-Gang Zhang
Journal:  Gut       Date:  2019-03-02       Impact factor: 23.059

6.  The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression.

Authors:  Smruti Pushalkar; Mautin Hundeyin; Donnele Daley; Constantinos P Zambirinis; Emma Kurz; Ankita Mishra; Navyatha Mohan; Berk Aykut; Mykhaylo Usyk; Luisana E Torres; Gregor Werba; Kevin Zhang; Yuqi Guo; Qianhao Li; Neha Akkad; Sarah Lall; Benjamin Wadowski; Johana Gutierrez; Juan Andres Kochen Rossi; Jeremy W Herzog; Brian Diskin; Alejandro Torres-Hernandez; Josh Leinwand; Wei Wang; Pardeep S Taunk; Shivraj Savadkar; Malvin Janal; Anjana Saxena; Xin Li; Deirdre Cohen; R Balfour Sartor; Deepak Saxena; George Miller
Journal:  Cancer Discov       Date:  2018-03-22       Impact factor: 39.397

Review 7.  The Yin and Yang of Toll-like receptors in cancer.

Authors:  J-P Pradere; D H Dapito; R F Schwabe
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

8.  Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion.

Authors:  Emelie Karnevi; Roland Andersson; Ann H Rosendahl
Journal:  Immunol Cell Biol       Date:  2014-03-25       Impact factor: 5.126

9.  Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma.

Authors:  Na Li; Yang Li; Zengxun Li; Chongbiao Huang; Yanhui Yang; Mingxiao Lang; Junli Cao; Wenna Jiang; Yu Xu; Jie Dong; He Ren
Journal:  Int J Mol Sci       Date:  2016-06-03       Impact factor: 5.923

Review 10.  Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.

Authors:  Etienne D Foucher; Clément Ghigo; Salem Chouaib; Jérôme Galon; Juan Iovanna; Daniel Olive
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

View more
  26 in total

1.  The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer.

Authors:  Quaovi H Sodji; Dhanya K Nambiar; Vignesh Viswanathan; Rie von Eyben; Deana Colburg; Michael S Binkley; Caiyun G Li; Monica M Olcina; Daniel T Chang; Quynh-Thu Le; Amato J Giaccia
Journal:  Cancer Res Commun       Date:  2022-07-27

2.  Zebrafish Xenograft Model for Studying Pancreatic Cancer-Instructed Innate Immune Microenvironment.

Authors:  Xue Wang; Wei Li; Haowei Jiang; Cui Ma; Mengling Huang; Xiaona Wei; Wei Wang; Lili Jing
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

3.  SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment.

Authors:  Dalin Zhang; Aaron Lindstrom; Edward J Kim; Chang-Il Hwang; Madison Lee Hall; Tzu-Yin Lin; Yuanpei Li
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

4.  CeDR Atlas: a knowledgebase of cellular drug response.

Authors:  Yin-Ying Wang; Hongen Kang; Tianyi Xu; Lili Hao; Yiming Bao; Peilin Jia
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

5.  Anti-Cancer Activity Profiling of Chemotherapeutic Agents in 3D Co-Cultures of Pancreatic Tumor Spheroids with Cancer-Associated Fibroblasts and Macrophages.

Authors:  So-Dam Jang; Jeeyeun Song; Hyun-Ah Kim; Chang-Nim Im; Iftikhar Ali Khawar; Jong Kook Park; Hyo-Jeong Kuh
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

Review 6.  Cell Lineage Infidelity in PDAC Progression and Therapy Resistance.

Authors:  Antonia Malinova; Lisa Veghini; Francisco X Real; Vincenzo Corbo
Journal:  Front Cell Dev Biol       Date:  2021-12-02

Review 7.  Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review.

Authors:  Hong-Bo Li; Zi-Han Yang; Qing-Qu Guo
Journal:  Cell Commun Signal       Date:  2021-11-24       Impact factor: 5.712

8.  ANXA1 Contained in EVs Regulates Macrophage Polarization in Tumor Microenvironment and Promotes Pancreatic Cancer Progression and Metastasis.

Authors:  Nunzia Novizio; Raffaella Belvedere; Emanuela Pessolano; Silvana Morello; Alessandra Tosco; Pietro Campiglia; Amelia Filippelli; Antonello Petrella
Journal:  Int J Mol Sci       Date:  2021-10-13       Impact factor: 5.923

Review 9.  Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma.

Authors:  Aditi Kothari; Matthew J Flick
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 6.208

10.  Differential Expression of Polyamine Pathways in Human Pancreatic Tumor Progression and Effects of Polyamine Blockade on Tumor Microenvironment.

Authors:  Sai Preethi Nakkina; Sarah B Gitto; Veethika Pandey; Jignesh G Parikh; Dirk Geerts; Hans Carlo Maurer; Kenneth P Olive; Otto Phanstiel; Deborah A Altomare
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.